Benjamin G Hale

List of Publications by Citations

46 papers	2,668 citations	25 h-index	51 g-index
54 ext. papers	3,133 ext. citations	8.8 avg, IF	5.3 L-index

#	Paper	IF	Citations
46	The multifunctional NS1 protein of influenza A viruses. *Journal of General Virology*, **2008**, 89, 2359-2376	4.9	787
45	Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 14194-9	11.5	227
44	Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. *Journal of Virology*, **2010**, 84, 6909-22	6.6	129
43	Interplay between viruses and host sumoylation pathways. *Nature Reviews Microbiology*, **2013**, 11, 400-11	12.2	125
42	Innate immune evasion strategies of influenza viruses. *Future Microbiology*, **2010**, 5, 23-41	2.9	119
41	Differential contribution of PB1-F2 to the virulence of highly pathogenic H5N1 influenza A virus in mammalian and avian species. *PLoS Pathogens*, **2011**, 7, e1002186	7.6	105
40	Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 1954-9	11.5	84
39	Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. *MBio*, **2020**, 11,	7.8	81
38	Structure of an avian influenza A virus NS1 protein effector domain. *Virology*, **2008**, 378, 1-5	3.6	74
37	CDK/ERK-mediated phosphorylation of the human influenza A virus NS1 protein at threonine-215. *Virology*, **2009**, 383, 6-11	3.6	65
36	MHC class II proteins mediate cross-species entry of bat influenza viruses. *Nature*, **2019**, 567, 109-112	50.4	57
35	Species-specific antagonism of host ISGylation by the influenza B virus NS1 protein. *Journal of Virology*, **2010**, 84, 5423-30	6.6	56
34	Global Reprogramming of Host SUMOylation during Influenza Virus Infection. *Cell Reports*, **2015**, 13, 1467-1480	10.6	55
33	Mutations in the NS1 C-terminal tail do not enhance replication or virulence of the 2009 pandemic H1N1 influenza A virus. *Journal of General Virology*, **2010**, 91, 1737-42	4.9	54
32	Binding of influenza A virus NS1 protein to the inter-SH2 domain of p85 suggests a novel mechanism for phosphoinositide 3-kinase activation. *Journal of Biological Chemistry*, **2008**, 283, 1372-1380	5.4	53
31	A single amino acid substitution in the novel H7N9 influenza A virus NS1 protein increases CPSF30 binding and virulence. *Journal of Virology*, **2014**, 88, 12146-51	6.6	51
30	Antigen presentation kinetics control T cell/dendritic cell interactions and follicular helper T cell generation in vivo. *ELife*, **2015**, 4,	8.9	50

29	An influenza virus-triggered SUMO switch orchestrates co-opted endogenous retroviruses to stimulate host antiviral immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 17399-17408	11.5	47
28	Conformational plasticity of the influenza A virus NS1 protein. *Journal of General Virology*, **2014**, 95, 2099-2105	4.3	46
27	Functional Insights into ANP32A-Dependent Influenza A Virus Polymerase Host Restriction. *Cell Reports*, **2017**, 20, 2538-2546	10.6	38
26	A transient homotypic interaction model for the influenza A virus NS1 protein effector domain. *PLoS ONE*, **2011**, 6, e17946	3.7	37
25	Influenza virus sequence feature variant type analysis: evidence of a role for NS1 in influenza virus host range restriction. *Journal of Virology*, **2012**, 86, 5857-66	6.6	32
24	Strain-specific contribution of NS1-activated phosphoinositide 3-kinase signaling to influenza A virus replication and virulence. *Journal of Virology*, **2012**, 86, 5366-70	6.6	31
23	PI3K signalling during influenza A virus infections. *Biochemical Society Transactions*, **2007**, 35, 186-7	5.1	27
22	SARS-CoV-2 variants reveal features critical for replication in primary human cells. *PLoS Biology*, **2021**, 19, e3001006	9.7	26
21	Contribution of NS1 effector domain dimerization to influenza A virus replication and virulence. *Journal of Virology*, **2012**, 86, 13095-8	6.6	23
20	Viral and host factors required for avian H5N1 influenza A virus replication in mammalian cells. *Viruses*, **2013**, 5, 1431-46	6.2	22
19	An antiviral trap made of protein nanofibrils and iron oxyhydroxide nanoparticles. *Nature Nanotechnology*, **2021**, 16, 918-925	28.7	18
18	Influenza A viruses and PI3K: are there time, place and manner restrictions?. *Virulence*, **2012**, 3, 411-4	4.7	17
17	Manipulation of the unfolded protein response: A pharmacological strategy against coronavirus infection. *PLoS Pathogens*, **2021**, 17, e1009644	7.6	17
16	Interferon system deficiencies exacerbating severe pandemic virus infections. *Trends in Microbiology*, **2021**, 29, 973-982	12.4	16
15	Profiling host ANP32A splicing landscapes to predict influenza A virus polymerase adaptation. *Nature Communications*, **2019**, 10, 3396	17.4	15
14	Structure-Guided Functional Annotation of the Influenza A Virus NS1 Protein Reveals Dynamic Evolution of the p85Binding Site during Circulation in Humans. *Journal of Virology*, **2017**, 91,	6.6	15
13	Novel Bat Influenza Virus NS1 Proteins Bind Double-Stranded RNA and Antagonize Host Innate Immunity. *Journal of Virology*, **2015**, 89, 10696-701	6.6	13
12	Cation currents in human airway epithelial cells induced by infection with influenza A virus. *Journal of Physiology*, **2009**, 587, 3159-73	3.9	12

11	Human interactome of the influenza B virus NS1 protein. *Journal of General Virology*, **2017**, 98, 2267-2273	4.9	12
10	Unexpected Functional Divergence of Bat Influenza Virus NS1 Proteins. *Journal of Virology*, **2018**, 92,	6.6	7
9	Application of a Biologically Contained Reporter System To Study Gain-of-Function H5N1 Influenza A Viruses with Pandemic Potential. *MSphere*, **2020**, 5,	5	4
8	BRD9 is a druggable component of interferon-stimulated gene expression and antiviral activity. *EMBO Reports*, **2021**, 22, e52823	6.5	3
7	Antiviral immunity triggered by infection-induced host transposable elements.. *Current Opinion in Virology*, **2021**, 52, 211-216	7.5	2
6	SARS-CoV-2 Variants Reveal Features Critical for Replication in Primary Human Cells		2
5	Manipulation of the unfolded protein response: a pharmacological strategy against coronavirus infection		2
4	Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir. *Journal of General Virology*, **2021**, 102,	4.9	2
3	Influenza A viruses balance ER stress with host protein synthesis shutoff. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	2
2	IFITM3 incorporation sensitizes influenza A virus to antibody-mediated neutralization. *Journal of Experimental Medicine*, **2021**, 218,	16.6	1
1	Restriction factor screening identifies RABGAP1L-mediated disruption of endocytosis as a host antiviral defense.. *Cell Reports*, **2022**, 38, 110549	10.6	1